NICE has recommended mirvetuximab soravtansine, also known as Elahere, for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, marking the first new NHS treatment for this group in more than 20 years. The decision, announced on 4 June 2026, offers a new option for people whose cancer has stopped responding to standard chemotherapy.
A targeted approach for a difficult-to-treat cancer
Unlike chemotherapy, the treatment is designed to seek out a specific protein found on the surface of cancer cells and deliver a cancer-killing medicine directly to them. NICE said the therapy should be available for routine use in England, after reviewing evidence on its benefits and the impact it may have on patients’ day-to-day lives.
Women who took part in the evaluation said the treatment could make a meaningful difference compared with chemotherapy, which often requires frequent hospital visits and can cause extreme fatigue, hair loss, nausea and long-term nerve damage. Mirvetuximab soravtansine is given once every three weeks and was described as having a more manageable side-effect profile. NICE announcement
Why the decision matters for patients and the NHS
Platinum-resistant ovarian cancer is a challenging area of treatment, with limited options once standard chemotherapy no longer works. Marie-Claire Platt, director of research and policy at Ovarian Cancer Action, said women living with this disease have been left behind for too long. The recommendation could therefore widen access to a therapy that offers a different mechanism of action and a new route for clinicians treating this aggressive cancer.
The decision is also notable because it comes as medical research continues to push targeted treatments further into routine NHS care. In recent months, NICE has highlighted the growing role of innovative medicines and technologies in supporting patients while evidence is gathered and treatment pathways evolve. NICE news archive
What happens next
For patients and clinicians, the recommendation means a new NHS option is now on the table for a cancer type that has long been difficult to manage after chemotherapy resistance develops. The approval adds to a steady shift in oncology toward more precise treatments that aim to improve outcomes while reducing the burden of side effects and repeated hospital visits.
As implementation begins in England, attention will now turn to how widely the medicine is adopted in practice and whether it can help change the outlook for people diagnosed with resistant ovarian cancer.
